New data for Phase 1A CLTX CAR T brain cancer clinical trial
Filed with ASX · · 8 pages · English
Chimeric Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Chimeric Therapeutics
- Agreement with MD Anderson for Phase 1B CHM 0201 AML study
- Dosing completion in Phase 1A brain cancer clinical trial
- Chimeric to receive A$4.4 million introduction fee
- Positive data - CHM 0301 next-gen armoured NK cell platform
- CHM secures up to A$12.6m through SPP and placements
Later from Chimeric Therapeutics
- Entitlement Offer to raise approximately $10 million
- FDA clearance of IND for CHM 2101
- 1st patient dosed in Phase 1b recurrent glioblastoma trial
- Positive in vitro data for CHM 1301 CAR NK cells
- Chimeric receives $7.36M R&D tax incentive
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics